产品中心
PRODUCTS
This product is indicated for the control of hyperphosphatemia in CKD adults on dialysis.
This product is indicated for the treatment of chorea in Huntington's disease. Chorea in Huntington's disease is a rare autosomal dominant neurodegenerative disorder affecting the central nervous system (included in the 2018 China's First List of Rare Diseases). Symptoms include involuntary dance-like movements, cognitive impairment and mental disorders. Tetrabenazine is the world's first drug used to treat chorea in Huntington's disease.
Adjuvant therapy to levodopa/benserazide or levodopa/carbidopa for the treatment of Parkinson's disease and wearing-off phenomenon (symptom fluctuation) not adequately controlled by these standards of care
This product is mainly indicated for the treatment of depressive disorder. It is a serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressant that acts on 5-hydroxytryptamine (5-HT) transporter and norepinephrine (NE) transporter to inhibit 5-HT and NE reuptake.
This product is indicated for the treatment of depressive disorder and seasonal affective disorder and for the cessation of smoking due to nicotine addiction. In clinical practice, it is also used for the treatment of depressive episodes in bipolar affective disorder (used in combination with mood stabilizers) and attention deficit hyperactivity disorder; it has a certain effect on some sexual dysfunctions.
The efficacy of aripiprazole against schizophrenia has been established in short-term (4-week and 6-week) controlled studies involving schizophrenia patients. Physicians who choose aripiprazole for long-term treatment should regularly re-evaluate its long-term efficacy in individual patients.
Contact Us：
Room 1502-1506, Building D2, Nanshan iPark, No. 1001, Xueyuan Avenue, Changyuan Community, Taoyuan Street, Nanshan District, Shenzhen, China.
Follow Us
© COPYRIGHT 2021 Shenzhen Foncoo Pharmaceutical Co., Ltd. ALL RIGHTS RESERVED